These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37004887)

  • 81. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
    N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.
    Feagan BG; McDonald JW; Panaccione R; Enns RA; Bernstein CN; Ponich TP; Bourdages R; Macintosh DG; Dallaire C; Cohen A; Fedorak RN; Paré P; Bitton A; Saibil F; Anderson F; Donner A; Wong CJ; Zou G; Vandervoort MK; Hopkins M; Greenberg GR
    Gastroenterology; 2014 Mar; 146(3):681-688.e1. PubMed ID: 24269926
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
    Khanna R; Bressler B; Levesque BG; Zou G; Stitt LW; Greenberg GR; Panaccione R; Bitton A; Paré P; Vermeire S; D'Haens G; MacIntosh D; Sandborn WJ; Donner A; Vandervoort MK; Morris JC; Feagan BG;
    Lancet; 2015 Nov; 386(10006):1825-34. PubMed ID: 26342731
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Adalimumab therapy in children with Crohn disease previously treated with infliximab.
    Cozijnsen M; Duif V; Kokke F; Kindermann A; van Rheenen P; de Meij T; Schaart M; Damen G; Norbruis O; Pelleboer R; Van den Neucker A; van Wering H; Hummel T; Oudshoorn J; Escher J; de Ridder L;
    J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):205-10. PubMed ID: 25286063
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
    Lovell DJ; Ruperto N; Goodman S; Reiff A; Jung L; Jarosova K; Nemcova D; Mouy R; Sandborg C; Bohnsack J; Elewaut D; Foeldvari I; Gerloni V; Rovensky J; Minden K; Vehe RK; Weiner LW; Horneff G; Huppertz HI; Olson NY; Medich JR; Carcereri-De-Prati R; McIlraith MJ; Giannini EH; Martini A; ;
    N Engl J Med; 2008 Aug; 359(8):810-20. PubMed ID: 18716298
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
    Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
    J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis.
    Lee YH; Woo JH; Rho YH; Choi SJ; Ji JD; Song GG
    Rheumatol Int; 2008 Apr; 28(6):553-9. PubMed ID: 17943257
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
    Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
    Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
    Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP;
    Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
    Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
    Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn's disease patients with perianal lesions: a systematic review.
    Carnovale C; Maffioli A; Zaffaroni G; Mazhar F; Battini V; Mosini G; Pozzi M; Radice S; Clementi E; Danelli P
    Expert Opin Biol Ther; 2020 Mar; 20(3):239-251. PubMed ID: 31971447
    [No Abstract]   [Full Text] [Related]  

  • 99. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
    Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.